Zynerba Pharmaceuticals, Inc. is an orphan-focused, neuropsychiatric biopharmaceutical company based in Devon, PA. They are dedicated to developing innovative transdermal cannabinoid treatments for patients with rare neurological diseases, with a particular focus on improving the lives of those battling certain rare conditions.
Recently acquired by Harmony Biosciences, Zynerba Pharmaceuticals is at the forefront of pioneering cannabinoid therapies for neuropsychiatric conditions. Their ongoing RECONNECT clinical trial is open for recruitment, offering patients, families, and healthcare providers an opportunity to learn more about Fragile X syndrome and access potential treatments. With a mission to advance science and improve connections, Zynerba Pharmaceuticals is committed to addressing unmet medical needs in the field of rare disorders.
Generated from the website